Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Caficrestat by Applied Therapeutics for Cardiomyopathy: Likelihood of Approval
Caficrestat is under clinical development by Applied Therapeutics and currently in Phase III for Cardiomyopathy. According to GlobalData, Phase III...
Caficrestat by Applied Therapeutics for Diabetic Peripheral Neuropathy: Likelihood of Approval
Caficrestat is under clinical development by Applied Therapeutics and currently in Phase III for Diabetic Peripheral Neuropathy. According to GlobalData,...
Caficrestat by Applied Therapeutics for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Caficrestat is under clinical development by Applied Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...
Gavorestat by Applied Therapeutics for Unspecified Metabolic Disorders: Likelihood of Approval
Gavorestat is under clinical development by Applied Therapeutics and currently in Phase III for Unspecified Metabolic Disorders. According to GlobalData,...
Caficrestat by Applied Therapeutics for Cardiomyopathy: Likelihood of Approval
Caficrestat is under clinical development by Applied Therapeutics and currently in Phase III for Cardiomyopathy. According to GlobalData, Phase III...
Risk adjusted net present value: What is the current valuation of Applied Therapeutics's Gavorestat?
Gavorestat is a small molecule commercialized by Applied Therapeutics, with a leading Pre-Registration program in Galactosemia. According to Globaldata, it...